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A Clinical Trial Using Methylation Age
to Evaluate Current Antiaging Practices
Josh Mitteldorf1,2
Abstract
Recent advances in the technology of ‘‘aging clocks’’ based on DNA methylation suggest that it may be
possible to measure changes in the rate of human aging over periods as short as a year or two. To the extent that
methylation (and other biomarkers) are valid surrogates for biological age, the testing of antiaging interventions
has thus become radically cheaper, faster, and more practical. Together with colleagues at UCLA, I have
initiated a clinical trial to evaluate some of the most popular antiaging strategies currently deployed by ‘‘early
adopters’’ in the lay community of personal health activists. We are recruiting 5000 subjects, age 45–65, and
interviewing them in detail about their diet, drugs and supplements, exercise, social, and other practices that
plausibly contribute to modulate the rate of aging. They agree to submit blood samples for analysis of meth-
ylation age at the beginning, middle, and end of a 2-year test period. Primary endpoint is the difference in
methylation age over the course of 2 years. We are in the process of developing a specialized clock, optimized
for individual differences over time. Results will be viewed as an exploratory study to identify synergistic
combinations of age-retarding treatments. It is our expectation that there is a great deal of redundancy in the
strategies that have been researched and promoted to the aware public; thus, most combinations can retard the
rate of aging by only a few percent, consistent with the best known single measures. However, we hope that
among the many strategies that our subjects have adopted, there will be some combinations that synergize and
achieve age retardation by ‡25% or more. A mock-up analysis of computer-generated data has been performed
to fix parameters of the study, and confirm that such combinations will be able to be detected with good proba-
bility, should they exist. All data (redacted for privacy) will be open sourced, available to the scientific
community and to the public.
Keywords: methylation, epigenetic, clock, antiaging, testing
Introduction
In this article, I argue that
(1) testing, more than development, is the bottleneck in
the flow of knowledge about human antiaging;
(2) single interventions are unlikely to afford major in-
crements in life expectancy in humans;
(3) interactions among combinations of known antiaging
interventions are the most important unknown in the
field;
(4) the daunting number of combinations may be tamed
by enrolling large numbers of early adopters who are
already using diverse combinations of strategies;
(5) the newest methylation clock, called ‘‘DNAm Phe-
noAge,’’ has the potential to tell us which of these
people are best succeeding in their quest to slow the
aging clock;
(6) further optimization of this clock, specialized to the
proposed application, is feasible; and
(7) exploratory data analysis can be done to identify the
best combinations of known interventions that are
already being deployed by members of the commu-
nity, which actively seeks to enhance their long-term
health.
These ideas have been integrated into the design of a
clinical trial based on collection of information about what
well-informed and highly motivated individuals are already
doing to slow their own aging. We do not ask participants to
do anything differently from what they are already doing;
this is a clinical trial based on questionnaires and
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methylation testing only. The project has benefited from
generous contributions of time and an in-kind donation from
Zymo Research, which has agreed to provide methylation
testing.
Background
What strategy or combination of strategies has the most
potential for extending human life span? In the past, an-
swering this question with epidemiological studies has been
enormously slow and expensive; hence, we have relied on a
patchwork of reasonable guesses, based on animal studies
and biochemistry, rather than human epidemiology. To
evaluate an aging intervention in humans would require
treating a test group and identifying a comparable untreated
control group. Then, there is a long latency period before a
small percentage of the control group dies of age-related
disease and (if the treatment is effective), a smaller per-
centage of the test group dies during the same period. Sta-
tistical significance depends on the difference between the
small mortality rates in these two groups. Only the sub-
jects who die offer statistical information, while the larger
number of subjects who do not die are a cost of doing
business.
A numerical example will help you see why epidemio-
logical studies of age-related mortality are so slow and
expensive. Suppose you start with 10,000 sixty-year-olds.
You assign 5000 to your test group and another 5000 to
your control group. If you wait 10 years, you expect 320 of
the controls to die in that time. Suppose that your anti-
aging treatment effectively slows the rate of aging decline
by 20%. (You would certainly like to be able to detect
effects of such magnitude.) The result would be that in the
treated group, the expected number of people who die
might be 255 instead of 320. The difference between 255
and 320 is marginally statistically significant by the
standard criterion (p < 0.05). The numbers 320 and 255
are averages, and in a real test the actual results would be
larger or smaller than these averages. There is a 20%
probability that the numbers in the test and control groups
would be too close to detect a significant difference, which
is to say that this study with this number of subjects would
have an 80% chance of detecting the efficacy of your
intervention.
Following 10,000 people for 10 years costs *$100
million at an American medical school. One might reduce
the numbers by starting with 75-year-olds rather than 60-
year-olds, because the mortality rate of the control group
is much higher, offering more statistical certainty. But this
may introduce a bias, since, there are treatments that work
for 60-year-olds that do not work for 75-year-olds.
Given the prohibitive cost and time delays, epidemio-
logical testing of any substantial number of treatment
combinations has been out of question. Hence, antiaging
science has relied on a hierarchy of test animals, from yeast
at the bottom of the pyramid to mice at the top. Only a few
studies have been performed with dogs, and just two repli-
cates with Rhesus monkeys; the latter at enormous expense
with marginal results.1,2
Recent improvements in the accuracy of age estimation
based on methylation offer the possibility of disruptive change
in the way antiaging treatments are evaluated. A much smaller
test population is needed, because every subject contributes
data, not just the ones who have died. The time required for
the study is reduced from decades to years, and the cost is
greatly reduced. It has been estimated3 that the time necessary
for a study is reduced by a factor of 10 and the cost by a factor
of 100.
Methylation testing has not been used previously to
evaluate any health intervention; there is evidence but yet no
proof that treatments extending life span will tend to retard
methylation age, or, conversely, that treatments that retard
methylation age will tend to extend life span. Nevertheless,
we have chosen to take a chance on an unproven test par-
adigm because the implications of a successful trial justify
the risk. We regard the test both as a proof of principle that
methylation testing can be used to evaluate antiaging mea-
sures in humans and as an exploratory study to identify
promising combinations of measures already in use.
Our Test Population
A loose community already exists of thousands of people
who identify as early adopters, and are currently experimenting
on themselves in the hope of extending their life spans and
health spans. These people are generally well informed of the
latest research findings, but they have different belief systems,
different information, and different resources; hence, there is a
good deal of variation in their regimens of diet, exercise, sup-
plements, and prescription medications. We will be recruiting
subjects from the following sources:
 Longecity
 Gerontology Research Group
 Customer base of Life Extension Foundation
 Aging Matters, FoundMyFitness, Self-hacked, Rogue
Health, and other blogs
 A4M, Rejuvenation Biotech, and RAADfest annual
meetings
Optionally, individual profiles may be linked to genomic
information. There is reason to believe that different sub-
jects respond to medications, exercise, and diet in different
ways, and to the extent that this depends on genetic differ-
ences, the information might lay the foundation for future
science of individualized medicine.4
Testing, Not Development, Is the Bottleneck
A great number of techniques have been discovered for
extending life span in invertebrate animal models. A smaller
but substantial number have been validated in rodents.
Many of these have been tried in humans and are proven
safe. A substantial database of these has been established at
Geroprotectors.org.5 With few exceptions, nothing is known
about their long-term effects in humans. In addition, there
are substances that have shown promise in small human
trials that remain unexplored and unreproduced.6,7
There exists a common perception that none of these will
have dramatic effects on human life span, and that greater
breakthroughs remain to be discovered. This may be true or
not; we cannot know at present. If it is true, then any future
















































they are accepted into (preventive) medical practice. If the
discovery is rather conventional, it is unlikely to produce
paradigm-breaking results; on the contrary, if the idea were
profoundly new and innovative, they will not be accepted
without extensive testing, and conventional epidemiological
testing would undoubtedly regard as prohibitively expensive
for high-risk innovations. In either case, the ability to test
for antiaging benefits cheaply and quickly will be essential.
The following is a partial list of treatments we have in-
cluded in our questionnaire:
 Calorie restriction
 Various fasting schedules
 Various diet regimens, including low carbohydrate,
low protein, low fat, vegetarian, high fiber, Atkins type,
Mediterranean, paleo, and Pritikin
 Various exercise regimens, including aerobic, resistance
training, interval training, and stretching
 Yoga, tai chi, meditation
 Family and work environments
 Prescription drugs, including metformin, rapamycin,
statins, angiotensin inhibitors, and deprenyl
 Nonsteroidal anti-inflammatory drugs (NSAIDs)
 Various vitamins
 Minerals, including magnesium, chromium, zinc, se-
lenium, and iodide
 Hormones and prehormones, including DHEA, mela-
tonin, SAMe, CoQ10, pregnenolone, and NAC
 Herbs and supplements, including fish oil, ashwagandha,
rhodiola, bacopa, mushroom derivatives, fo-ti, and gin-
seng.
Combining Treatments
Many individual treatments are known that modestly
extend life span in rodents and, presumably, in humans, but
the interactions among these treatments have barely been
explored. Most of the people in our sample group use many
of these treatments, based on vague notions of bet-hedging
and an unarticulated intuition that perhaps the benefits will
be additive. But it is unlikely that the benefits add linearly; if
they did, we would have seen by now some dramatic and
obvious examples of age reversal. There is much redun-
dancy among the mechanisms of action of the known in-
terventions, so the underlying metabolic pathways tend to
become saturated. Hence, our default expectation is that
most combinations of treatments will offer little more ben-
efit than any of the treatments separately.
But more rarely, we may find pairs of interactions that sy-
nergize; in other words, in a few cases we might expect that the
mean life extension from two treatments A and B is equal to or
even greater than the sum A + B of the benefits from the treat-
ments separately. For example, rapamycin and metformin are
reported to synergize,8 and angiotensin inhibitors work through
a pathway distinct from either of these.9
It is unlikely that any single remedy will completely neu-
tralize or reverse aging. Testing interactions among combi-
nations of treatments may be even more important than testing
treatments separately. But for even a handful of treatments,
the number of possible interactions between them presents a
daunting challenge. Separate trials for each possible combi-
nation are prohibitively costly and complicated.
Based on this reasoning, we have decided to plan our
study around a great number of independent variables. We
hope to use principles of multiplexing and multivariate
analysis to make sense of the data that are generated.
Our first priority in analysis will be to focus on outliers,
the subset of the test population who have scored the
greatest decrease in methylation age over the 2-year test.
(Even if none of the treatments actually lead to age reversal,
the standard error of the test is such that over a 2-year time
span there will be a substantial number of people who ap-
pear to have reduced their biological age.) This subset will
be enriched in subjects who have had the greatest success in
reducing the rate of aging, and we can look for common-
alities among the programs of people who have been most
successful. We will consider our exploratory program to be
successful to the extent that we identify a small number of
combinations of treatments that are candidates for more de-
tailed study in the future. But a null result will also be inter-
esting. If there are no outliers (no fat tail in the distribution),
this will indicate that no combination of the strategies cur-
rently available offers an outstanding anti-aging benefit.
History of Methylation Clocks
Cytosine is one of the four nucleic acids that combine to
form DNA, and in most higher organisms, some of the cy-
tosine within DNA has an extra methyl group, making 5-
methyl cytosine. Methylation is modulated not within genes
but at adjacent regions with high concentrations of cytosine,
called CpG islands. High levels of methylation tend to
suppress expression of adjacent genes, and can also have
effects (by mechanisms unknown) on expression of genes
that are not nearby.
DNA methylation is the best studied and easiest to measure
among many known mechanisms of epigenetic control. It has
been known since the 1990s that human methylation patterns
vary systematically, both by tissue type and by age. There is
ongoing discussion whether changing methylation patterns are
a driver of aging or a passive marker.10
The first practical methylation clocks were developed by
Hannum and independently by Horvath,11 building on an idea
of Teschendorff et al..12 Horvath identified patient records for
methylation measurements of tissue samples from 8000 indi-
viduals with associated ages. Methylation is recorded as a
number between 0 and 1 for each cytosine, indicating the
proportion of that site that is methylated. He scanned the
available genome for sites that changed most with age, and
varied least among different tissue types. His algorithm iden-
tified 353 sites and derived a set of 353 multipliers, such that
multiplying levels of methylation at each site and adding the
products produced a number that could be mapped onto
chronological age. About 55% of the sites gain methylation
with age and 45% lose methylation.
The original Horvath clock correlates 0.95 with chrono-
logical age. The standard error in predicting any one individ-
ual’s age is –4 years. Averages of N individuals increase the
accuracy of the clock by ON, so that the average of 100 in-
dividuals is accurate to 0.4 years. For our purposes, the rele-
vant question is as follows: measuring the same individual at
two different times, how accurate is the difference in Horvath
age compared with the elapsed time? There are little data on
this thus far, but we might safely assume that it is <4 years,















































since standard error of 4 years represents mostly individual
departures from the average, and the PhenoAge clock de-
scribed below is somewhat more accurate. For calculations in
this document concerning accuracy and numbers of subjects
needed, I have assumed that an optimized methylation clock
will measure differences over time for the same individual with
an accuracy of 1.5 years.
A methylation map of the genome represents 28 million
numbers between 0 and 1, representing the proportion (in a
sample of cells) of each of 28 million CpG sites that are
methylated. Of these 850,000 are covered in the EPIC test
from Illumina, Inc, the largest commercial kit for methyla-
tion profiling. This represents <3% of all CpGs, but the
selection is concentrated in areas that control expression of
local (27%) and distal (7%) genes.13 A ‘‘clock’’ is merely an
algorithm for calculating age from these 850,000 numbers.
In practice, only a few hundreds of the 850,000 are used in
the clock function, a sample of a sample.
Concurrently with Horvath, Hannum et al.14 independently
developed a clock that was more accurate and more parsimo-
nious when specialized to blood samples. Five years on, there
are several other clocks based on methylation. The smallest is
based on a single site, but several others sample hundreds of
methylation sites each. All clocks developed so far are linear in
the sense that they are simple weighted averages of the meth-
ylation levels of (several hundred) sampled sites. The weighted
average is not yet an age, because methylation levels do not
change linearly over a life span; after the weighted average is
computed, another function is derived (empirically) that maps
the readout as an age. In other words, a clock consists of several
hundred multiplier numbers, together with a function that
translates the weighted average into ‘‘years.’’
The limitation to weighted averages is unnecessarily re-
strictive. It is probable that accuracy can be achieved be-
yond any of the extant clocks using separate nonlinear
functions for each methylation site (see Improvements and
Adaptations of the Horvath Clock section).
As of this writing, the best predictor of age-related de-
cline is the Levine/Horvath clock15 also called DNAm
PhenoAge. It is based on 513 methylation sites, and it is
calibrated not to chronological age but to a tighter measure
of age-based health, derived from blood lipid profiles, in-
flammatory markers, insulin resistance, and other markers of
age-related health, a composite that Horvath calls ‘‘pheno-
typic age.’’ The PhenoAge clock is (by design) less well
correlated with chronological age than the original, but it is
better able to predict mortalityand age-related morbidity than
either the classic Horvath clock or chronological age itself.
By this measure, the scatter has been greatly reduced. The
PhenoAge clock is not yet optimized for the purpose of
assessing year-to-year changes within an individual, nor is it
specialized to the age range 45–65 of our study. We plan to
use PhenoAge as a starting point to develop a clock spe-
cialized for our study.
Statistical Evidence That the PhenoAge Clock
Reliably Measures Biological Age
The most direct evidence comes from a meta-analysis based
on historic data. Starting with frozen blood samples from the
past, Levine and Horvath calculate PhenoAge as it was when
the sample is drawn, and compare their results with the health
and mortality histories after the blood draw. The Horvath Clock
‘‘predicts’’ the remaining life expectancy of the subjects more
accurately than their chronological age.16 There are less data
available for the new PhenoAge clock, but there are strong
indications that it performs much better than the Horvath clock
for this purpose.10,17
Also, many of the life styles that promote long life have
been confirmed to slow the PhenoAge clock, while, con-
versely, obesity and high blood pressure and insulin resis-
tance have been found to accelerate aging as measured by
the PhenoAge clock. Better statistics are available for the
original Horvath clock, which has been studied for 5 years,
but indications are that the PhenoAge clock performs better.
Figure 1 is copied from Horvath and Raj.10
 Epigenetic age correlates with progression of Alzhei-
mer’s and Parkinson’s disease16
 Same for arthritis18
 Menopause moves the methylation clock forward. Early
menopause is associated with accelerated methylation
aging, and late menopause with younger methylation age.
 Epigenetic age is accelerated by obesity, blood sugar,
insulin, and inflammation.
 Epigenetic age is retarded by carotene supplementation,
exercise, education, and by diets high in vegetables,
fruits, and nuts.
 Stem cell transplants lower epigenetic age dramatically
(from a study of leukemia patients19). Epigenetic age is
set back *8 years for a short period, but then accel-
erates to a set forward a few years after treatment.
(All the above claims drawn from Horvath and Raj.10)
Theoretical Foundation of the Horvath Clock
The original Horvath clock was developed by a statistical
process that took into account only chronological age. It was
later validated as a better predictor than chronological age
for risk of all-cause mortality and several diseases of old
age. This fact is powerful evidence that methylation is
measuring something fundamental about the aging process.
If an individual’s methylation age is higher or lower than his
chronological age, the difference is a predictor of his disease
risk and how long he will live. This can only be true if
methylation is associated with a fundamental cause of age-
related decline, and is not merely a ‘‘marker’’ of aging.
Development of an embryo to a fetus to a child to an adult
takes place under epigenetic control.20,21 An emerging theory
the last 7 years is that the epigenetic program continues after
growth ends, and that aging is the result. de Magalhães,22
Rando and Chang,23 Blagosklonny,24 Johnsonet al.,25 and
Mitteldorf26 all have independently proposed an epigenetic
basis for aging. This fits to the observed fact that much of the
change in methylation is continuous, from development
through aging.27 According to the epigenetic theory, the root
cause of aging is that different sets of genes are expressed at
different times of life. Whether the epigenetic changes re-
sponsible for aging constitute an evolved adaptation26,28 or
whether it is a kind of inertia that continues past its usefulness
to the individual22,29 is an interesting theoretical question, but
irrelevant to the question of the clock’s usefulness in testing
















































aging lends credence to the idea that methylation should be
closely associated with biological age.
Parabiosis experiments30–32 support the idea that factors
circulating in the blood can rejuvenate remote tissues. This
is indirect support for the epigenetic foundations of aging,
because these blood factors come from gene expression in
cells—especially but not exclusively endocrine cells. The
experiments suggest that aging at the cellular level is revers-
ible through a young signaling environment. It is to be hoped
that epigenetic reprogramming of endocrine cells will trigger
release of youthful signals. More modestly, slowing of the
epigenetic clock ought to slow changes in the age-dependent
circulating signals, retarding aging systemwide.
Skepticism, Doubts, and Counterarguments
(A) Methylation clock untethered to gene expression—
Methylation sites queried in the aging clocks have been
derived empirically without reference to theory or to
biochemistry. Attempts to correlate these sites with ex-
pression of known genes have achieved quite limited
success thus far.13 Expression of some inflammatory cy-
tokines has been associated with increased methylation
age, and, paradoxically, telomerase expression has been
linked to accelerated methylation aging.10 But most sites
of the Horvath, Hannum, and Levine clocks have yet to be
linked to gene expression. This constitutes a gap in our
understanding of how the clocks work, and cause for
questioning whether their basis is fundamental to aging.
The most parsimonious explanation is that methylation
controls expression of genes far from the methylation site
in ways that have yet to be catalogued.
(B) ‘‘Epigenetic drift’’—Many authors still write about
changes in methylation during aging as ‘‘epigenetic
drift,’’33 as though these changes were wholly stochastic.
This represents an attempt to reconcile the self-
destructive potential of epigenetic changes over a life
span with a perspective dismissive of the idea that pro-
grammed aging might be an evolutionary adaptation.
While it is true that gene expression does become more
random with age, it is also true that there are specific gene
expression changes associated with aging—the methyla-
tion clock is based on such programmed changes. Many
of the known changes appear to have wholly detrimental
effects on the metabolism, and indeed some of these
changes correspond to the human aging phenotype.17
(C) Perhaps gene expression changes are a response to
damage, the body’s attempt to mitigate aging. This is
the suspicion that haunts the aging clock. If this is the
case, interventions that thwart the mitigation would come
out looking like age reversal, but in fact they would have
FIG. 1. Comparison of three DNA methylation-based biomarkers of aging. The multitissue DNA methylation-based
(DNAm) age estimator (blue line), also known as Horvath’s clock, stands out in terms of its correlation with chronological
age across multiple tissue types, its high accuracy in children, its strong correlation with gestational age (differentiation day)
in neuronal cell culture models, and the homogeneity of its age estimates across tissues, for example 30 tissue samples
collected from a supercentenarian (>110 years). The phenotypic age estimator (green line) or DNAmPhenoAge stands out in
terms of its predictive accuracy for time to death, its association with smoking status, and its association with various
markers of immunosenescence. In general, DNAm PhenoAge and DNAm Age as calculated by the single-tissue age
estimator known as Hannum’s clock (red line) outperform other blood-based biomarkers in regard to life span prediction.















































the opposite effect, increasing risk of disease and mor-
tality. Support for this idea comes from the prejudice that
says ‘‘The body would never purposefully destroy itself.’’
The strongest evidence for this idea is that genetic variations
associated with longer telomeres are correlated with older
methylation age.10 But many others among the programmed
changes have been shown to be detrimental. For example,
‘‘DNA PhenoAge acceleration was found to be associated
with increased activation of pro-inflammatory and interferon
pathways and decreased activation of the transcriptional and
translational machineries, the DNA damage response and
nuclear mitochondrial signatures’’ (quote from Horvath and
Raj10 referenced therein to Levine et al.17).
(D) Not all antiaging interventions affect the PhenoAge
or Horvath clocks. This could be a substantial problem if
it turns out that there are effective antiaging strategies that
work in ways undetectable by the PhenoAge clock or,
conversely, if some strategies are able to set back the
PhenoAge clock without reducing risk of age-related
disease. ‘‘For example, within a 9-month follow-up period,
the substantial weight loss resulting from bariatric surgery
was not associated with a reduction in epigenetic age of
human liver tissue samples’’ (quote from Horvath and
Raj10; referenced therein to Horvat et al.34). To the extent
we think that bariatric surgery is a legitimate antiaging
strategy, this hints at a problem that could be more general.
Improvements and Adaptations
of the Horvath Clock
For present purposes, the PhenoAge clock is a substantial
improvement on the original Horvath clock, attained by
calibrating it against health indicators and not just chrono-
logical age. There are at least three more ways in which the
methylation age test can be improved:
(A) The original clock and all its successors thus far
have been based on simple linear combinations of dif-
ferent methylation sites. But we know that different meth-
ylation sites change with age on different schedules. With
mathematics that is just a bit more complicated, it is possible
to adapt the clock’s sensitivity to each site in accordance
with its unique age trajectory. This change to the algorithm
ought to improve the clock’s accuracy for any application.
(B) The clock might be specialized to the application of
testing antiaging effects on individual humans; that is,
comparing biological age for the same individual at two
different times. Some of the scatter in the plot of DNA-
mAge is due to variation from one individual to another,
and some is due to other random factors that do not de-
pend on the individual. In the past, there were little data
available for the same individual at two different times,
but this is changing, and now it is feasible to separate the
two kinds of scatter. The clock can then be specialized to
report age differences even more accurately.
(C) Again, for the particular application proposed, there
is no need for a clock that works generally on any age,
from prebirth to centenarian. If all of the people in the
study are between the ages of 45 and 65, then the clock
might be specialized to be more accurate in this age
range, at the expense of losing accuracy for younger and
older subjects—who are not part of the study. It may be
worthwhile to take this idea even further and have spe-
cialized subclocks calibrated for narrow age ranges. De-
rivation of the algorithms of these specialized clocks will
demand more training data than is now available.
Tightening the accuracy of the clock affects the amount
of information that can be derived from a given number of
experimental subjects. The DNAm PhenoAge clock corre-
lates 96% with phenotypic age. If this can be raised to 98%,
the number of human subjects required to detect a given
antiaging benefit is reduced by half. Conversely, for the
same effort and expense, we will be able to derive more
information about more treatment strategies.
If we can indeed construct a clock with 98% correlation
accuracy, a new benefit will be available: Accuracy then will
be approaching the point where a single individual might
detect benefits over the course of 2 years. This will be a
gateway to individualized medicine, as individuals will be
able to use the methylation clock for feedback on whatever
strategies they use consistently. Self-experimentation is el-
evated from guesswork based on subjective response in real
time to a science based on objective measurement.
How Many Subjects Are Needed?
This is an exploratory study, and we do not know what we
will find. That said, it is worthwhile to target the size of the
study based on a hypothesized benefit, planning for sufficient
statistical power to detect that benefit should it exist in our data.
To this end, I created a computer simulation based on the
following assumptions:
 There are 20 plausible antiaging measures, each of which
has a prevalence between 0.2 and 0.8 in the population
we are studying. They are distributed through the popu-
lation independently.
 The 20 measures have an average benefit of 0.05, in-
terpreted to mean that they slow the rate of aging by
5%. The benefits are normally distributed with a stan-
dard deviation of 0.05, so that the best of them is likely
to slow aging by 15%, while some of the worst actually
accelerate aging.
 Almost all combinations of these benefits are redundant.
The combined effectiveness of a set of antiaging measures
is equal to the best single measure pursued separately.
 But (by assumption) one combination of three [out of
the C(20,3) = 1140 possible triples] has an extraordi-
nary synergy and slows aging by X%. If such a magic
triplet exists, it is the most compelling purpose of our
study to assure that it is identified.
As observed above, the best available methylation clocks
have uncertainty for each individual test of *1.5 years. The
difference between two measured ages will have an uncertainty
O2 times higher than this, under the worst case assumption that
the two errors are independent random variables. But aging
markers are now recognized as an important research tool, and
several groups are making rapid progress toward development
of new markers (Horvath, personal communication; Kennedy,
personal communication). For purposes of this calculation,
I have assumed that a specialized clock can be developed,
which measures the difference in age for a given individual
















































Without going through the full simulation, the follow-
ing calculation can provide a rough guide to what can be
achieved with 5000 subjects. Every given triple of aging
measures will be adopted on average by *1/8 of the
subjects (½ · ½ · ½). We assumed that the distribution of
the errors in measured ages has a standard deviation of 1.5
years, and averaging 625 subjects, the standard deviation
of the mean is *1.5/O625 = 0.06 years. We need three
standard deviations for an effect to stand out above the
noise, and that is 0.18 years. Over a 2-year time period,
under ideal assumptions, we would be able to detect (0.18/
2 years), which is a 9% deceleration of the rate of aging.
The calculation below shows that the simulated result is
somewhat less sensitive than this, and in real life with
dropouts, inaccurate reporting, individual variation, and
other departures from ideal assumptions, it may be rea-
sonable to detect a 20% or 30% effect on the rate of aging
at the smallest. If a combination of available treatments
exists that offers benefits of this magnitude, we would
certainly be interested to know about it.
In the simulated analysis, I compared the average benefit
for each of the possible triples, and counted a success if the
one presumed synergistic combination was ranked first or
second (out of 1140) in analysis of the computer-generated
data. Since both generation and analysis of the data are quick
once the program is written, I was able to evaluate many
thousands of scenarios to estimate the average probability
that the single synergistic triple would be detected.
Based on these assumptions, we calculate the number of
experimental subjects needed to assure an 80% chance of
detecting a synergistic benefit of a given size. The result is
plotted in Figure 2.
Given the planned size of our study (5000 subjects), what
is the probability of detecting a synergy of a given size?
This result is plotted in Figure 3.
How Will We Know if We Have Identified
a Synergistic Combination?
This is an exploratory study, and we will look at the data
on its face for suggestions of interesting patterns of any
kind. One disappointing but informative possibility is that
among this collection of well-informed early adopters, no
coherent subset has achieved more than a 15% deceleration
of the aging rate (+20 months biological age in the course of
24 months chronological age). The most promising result
will be the one outlined just above, namely the identification
of a combination of two or three or four antiaging measures
FIG. 2. The number of subjects needed to have an 80% assurance of detecting a synergy, plotted against the size of the
synergy on the x axis.
FIG. 3. For a study including 5000 subjects, what is the probability of detecting a three-way synergy as described above,
as a function of the size of the synergy.















































that synergize to offer age retardation of ‡25%. One sign
that this is the case would be a long, asymmetric tail on the
distribution of age retardation calculated for all possible
three-way combinations. The reason for this is as follows:
Imagine, as in the simulation above, a universe of 20 anti-
aging measures, of which each subject in the study has adopted
some and not adopted others. There are C(20,3) = 1140 triples
among these 20 measures. For each of these triples, calculate
the average age retardation for just that subset of individuals
who have adopted all three measures (no matter what other
measures they may also have adopted). Under the null as-
sumption of no synergy, the distribution of the 1141 age re-
tardations will look like Figure 4. (Of course, the averages are
calculated on results as measured, including a random error of
order 1.5 years, as assumed above.)
But if there is one combination of three that offers age
retardation of 25%, the same plot looks like Figure 5.
The synergistic triple is alone at the far right. The reason
for the long tail in the distribution connecting the synergistic
triple to the rest of the distribution is that there are 51 other
triples that overlap with the synergistic triple, sharing 2 of 3
measures in common. For each of these, about half of the
subjects counted in the average actually have deployed the
synergistic combination, pulling their average up.
Figures 4 and 5 are included merely as examples. Other
patterns might indicate other patterns of synergy, and we
plan to approach the data without preconceptions about what
it might reveal.
Summary
In the future, there will undoubtedly be exceptional strat-
egies that have substantial effects on life span but no effect on
methylation clocks. Conversely, there will be Type I errors—
strategies that set the methylation clock back and yet have no
effect on life expectancy. But we expect that these will be
exceptions. There is extant evidence for a substantial overlap
between interventions that extend life span and interventions
that decelerate the methylation clocks. Given that exploration
with this measure is projected to be 10 times faster and 100
FIG. 4. Distribution of average age retardation for subjects that include each of 1141 combinations of 3 measures out of a
universe of 20. Calculated under the assumption that there is no synergy, and all measures are mutually redundant.
FIG. 5. Calculated as in Figure 4 for the case where there is a single synergistic triple. Note the long tail that connects the
















































times cheaper than traditional epidemiology, it is worthwhile
to pursue methylation assessments now for all known and
suspected antiaging strategies.
If these projected savings are realized, human trials will
be less expensive (and, of course, more relevant) than rodent
testing for a large class of interventions. At present, there is
no methylation clock for mice with comparable accuracy to
the human clock, but clocks for rodents and other mammals
are under development in the Horvath laboratory. Such a
clock could slash the cost of rodent testing, so that a great
number of interventions could be tested with an unprece-
dented level of efficiency. (Calibration of a mouse clock
may not require the tens of thousands of subjects that have
been used for humans because we have inbred mouse pop-
ulations that are genetically homogeneous.)
High-throughput testing of the dozens of proposed anti-
aging interventions that are presently backlogged should
soon be a practical and affordable reality.
Author Disclosure Statement
The author is presently engaged in fundraising and recruit-
ing for this study.
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